hemotune makes a significant step forward: advancing into clinical trials after completing CHF 14 million Series B2 round

Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the incorporation of a new subsidiary in Leuven, Belgium. This strategic expansion marks another significant milestone in the company’s growth and commitment to serving its European customers.

Driving the future of non-surgical endometriosis diagnosis: Hera Biotech acquires Scailyte’s endometriosis diagnostic assets

Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the incorporation of a new subsidiary in Leuven, Belgium. This strategic expansion marks another significant milestone in the company’s growth and commitment to serving its European customers.

HEMEX opens subsidiary in Belgium, expanding its presence in the EU

Image of a town hall in Leuven, Belgium

Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the incorporation of a new subsidiary in Leuven, Belgium. This strategic expansion marks another significant milestone in the company’s growth and commitment to serving its European customers.

hemotune AG Achieves ISO 13485 Certification, Advancing Breakthrough Nanotechnology in Blood Purification for Improved Patient Care

Proud hemotune AG team showing ISO 13485 certificate

Schlieren, Switzerland, August 24th 2023 – hemotune AG, a pioneering MedTech startup revolutionizing blood purification with cutting-edge nanotechnology, proudly announces its attainment of ISO 13485 certification. The certification covers design and development, production, distribution, and service of medical devices for blood purification including coated colloidal nanoparticles and marks a significant milestone towards delivering its innovative blood purification technology to patients.

hemotune AG initiates joint feasibility project on the HemoSystem with AstraZeneca

Schlieren (Switzerland), 23rd March 2023 – hemotune AG, the Schlieren-based MedTech company known for its magnetic blood purification platform announces a joint feasibility project with the global pharmaceutical company AstraZeneca.

Reaching for the stars – ASPIVIX receives 510(k) clearance of Carevix™, Their Novel ATRAUMATIC Cervical Stabilizer from the U.S. FDA

HEMEX is proud to announce that our portfolio company ASPIVIX has received 510(k) clearance of Carevix™ from the U.S. Food and Drug Administration (FDA). ASPIVIX’s novel Cervical Stabilizer will allow millions of women across the USA access to significantly less painful treatments and IUD insertions.

Moving forward fast – ASPIVIX is finishing the 2022 with a new investment and a generous grant

We are thrilled to share that HEMEX is part of the investment consortium financing the series B1 of hemotune AG. At HEMEX, we look forward to support hemotune on the journey to making the HemoSystem available to patients globally. 

hemotune recognized as innovation leader in blood purification technology

We are thrilled to share that HEMEX is part of the investment consortium financing the series B1 of hemotune AG. At HEMEX, we look forward to support hemotune on the journey to making the HemoSystem available to patients globally.